Safety and Tolerability of Secukinumab in Patients with Active Ankylosing Spondylitis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials

被引：0
|
作者：
Deodhar, Atul A. [1 ]
Baeten, Dominique [2 ]
Sieper, Joachim [3 ]
Porter, Brian [4 ]
Widmer, Albert [5 ]
Richards, Hanno [5 ]
机构：
[1] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR 97201 USA
[2] Univ Amsterdam, Acad Med Ctr, Clin Immunol & Rheumatol, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Clin Benjamin Franklin, Berlin, Germany
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Novartis Pharma AG, Basel, Switzerland
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
SIGNIFICANTLY IMPROVES SIGNS; PLACEBO-CONTROLLED TRIAL; MONOCLONAL-ANTIBODY; INTERLEUKIN-17A; SYMPTOMS; PHASE-3;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2887
引用
收藏
页数：2
相关论文
共 50 条
  • [21] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT OF ENTHESITIS IN ANKYLOSING SPONDYLITIS PATIENTS: A POOLED ANALYSIS OF FOUR PIVOTAL PHASE 3 TRIALS
    Deodhar, Atul
    Schett, Georg
    Baraliakos, Xenofon
    Van den Bosch, Filip
    Gensler, Lianne
    Ostergaard, Mikkel
    Agawane, Shital
    Gupta, Ayan
    Mpofu, Shephard
    Fox, Todd
    Winseck, Adam
    Porter, Brian
    Shete, Abhijit
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 7 - 7
  • [22] SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE OVER LONG-TERM EXPOSURE (UP TO 4 YEARS) IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS - UPDATED POOLED ANALYSIS OF THREE PHASE 3 TRIALS
    Deodhar, A.
    Baraliakos, X.
    Marzo-Ortega, H.
    Sieper, J.
    Martin, R.
    Porter, B.
    Shete, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 727 - 727
  • [23] Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
    Baraliakos, Xenofon
    Van den Bosch, Filip
    Machado, Pedro M.
    Gensler, Lianne S.
    Marzo-Ortega, Helena
    Sherif, Bintu
    Quebe-Fehling, Erhard
    Porter, Brian
    Gaillez, Corine
    Deodhar, Atul
    RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 273 - 288
  • [24] Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
    Xenofon Baraliakos
    Filip Van den Bosch
    Pedro M. Machado
    Lianne S. Gensler
    Helena Marzo-Ortega
    Bintu Sherif
    Erhard Quebe-Fehling
    Brian Porter
    Corine Gaillez
    Atul Deodhar
    Rheumatology and Therapy, 2021, 8 : 273 - 288
  • [25] SECUKINUMAB DEMONSTRATES CONSISTENT SAFETY OVER LONG-TERM EXPOSURE (UP TO 3 YEARS) IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF THREE PHASE 3 STUDIES
    Deodhar, A.
    Baraliakos, X.
    Marzo-Ortega, H.
    Sieper, J.
    Gupta, A. D.
    Porter, B.
    Fox, T.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S107 - S107
  • [26] Apremilast: pooled safety analysis of three phase 3, randomized, controlled trials in patients with psoriatic arthritis
    Schett, G.
    Mease, P.
    Kavanaugh, A.
    Adebajo, A.
    Gomez-Reino, J.
    Wollenhaupt, J.
    Cutolo, M.
    Lespessailles, E.
    Shah, K.
    Hu, A.
    Stevens, R.
    Edwards, C.
    Birbara, C.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 122 - 122
  • [27] APREMILAST: POOLED SAFETY ANALYSIS OF THREE PHASE 3, RANDOMIZED, CONTROLLED TRIALS IN PATIENTS WITH PSORIATIC ARTHRITIS
    Mease, P. J.
    Kavanaugh, A.
    Adebajo, A. O.
    Gomez-Reino, J. J.
    Wollenhaupt, J.
    Cutolo, M.
    Schett, G.
    Lespessailles, E.
    Shah, K.
    Hu, C.
    Stevens, R.
    Edwards, C. J.
    Birbara, C. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 685 - 685
  • [28] Apremilast: pooled safety analysis of three phase 3, randomized, controlled trials in patients with psoriatic arthritis
    Schett, G.
    Mease, P. J.
    Kavanaugh, A.
    Adebajo, A. O.
    Gomez-Reino, J. J.
    Wollenhaupt, J.
    Cutolo, M.
    Lespessailles, E.
    Shah, K.
    Hu, C.
    Stevens, R.
    Edwards, C.
    Birbara, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 : 6 - 6
  • [29] Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis
    Deodhar, Atul
    Akar, Servet
    Curtis, Jeffrey R.
    El-Zorkany, Bassel
    Magrey, Marina
    Wang, Cunshan
    Wu, Joseph
    Makgoeng, Solomon B.
    Vranic, Ivana
    Menon, Sujatha
    Fleishaker, Dona L.
    Diehl, Annette M.
    Fallon, Lara
    Yndestad, Arne
    Landewe, Robert B. M.
    ADVANCES IN RHEUMATOLOGY, 2024, 64 (01):
  • [30] Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
    M. Elaine Husni
    Atul Deodhar
    Sergio Schwartzman
    Soumya D. Chakravarty
    Elizabeth C. Hsia
    Jocelyn H. Leu
    Yiying Zhou
    Kim H. Lo
    Arthur Kavanaugh
    Arthritis Research & Therapy, 24
12345